JP2025502861A5 - - Google Patents
Info
- Publication number
- JP2025502861A5 JP2025502861A5 JP2024540670A JP2024540670A JP2025502861A5 JP 2025502861 A5 JP2025502861 A5 JP 2025502861A5 JP 2024540670 A JP2024540670 A JP 2024540670A JP 2024540670 A JP2024540670 A JP 2024540670A JP 2025502861 A5 JP2025502861 A5 JP 2025502861A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- sucrose
- fxi
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210006206.X | 2022-01-05 | ||
| CN202210006206 | 2022-01-05 | ||
| CN202210053441.2 | 2022-01-18 | ||
| CN202210053441 | 2022-01-18 | ||
| PCT/CN2023/070573 WO2023131213A1 (zh) | 2022-01-05 | 2023-01-05 | 一种包含抗FXI/FXIa抗体的药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025502861A JP2025502861A (ja) | 2025-01-28 |
| JP2025502861A5 true JP2025502861A5 (https=) | 2026-01-15 |
Family
ID=87073189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540670A Pending JP2025502861A (ja) | 2022-01-05 | 2023-01-05 | 抗ＦＸＩ／ＦＸＩａ抗体を含む医薬組成物及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250179213A1 (https=) |
| EP (1) | EP4461749A4 (https=) |
| JP (1) | JP2025502861A (https=) |
| CN (1) | CN118382643A (https=) |
| TW (1) | TW202333789A (https=) |
| WO (1) | WO2023131213A1 (https=) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11066481B2 (en) * | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
| TW201802121A (zh) * | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| US20190367636A1 (en) * | 2017-01-19 | 2019-12-05 | Bayer Pharma Aktiengesellschaft | Novel stable formulation for fxia antibodies |
| EP3626266A4 (en) * | 2017-05-16 | 2021-04-07 | Jiangsu Hengrui Medicine Co., Ltd. | CTLA4 ANTIBODY PHARMACEUTICAL COMPOSITION AND USES THEREOF |
| EP3713965A1 (en) * | 2017-11-22 | 2020-09-30 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| PE20210462A1 (es) * | 2018-07-05 | 2021-03-08 | Bayer Ag | METODO PARA LA PRODUCCION DE GRANULOS LIOFILIZADOS QUE COMPRENDEN UN ANTICUERPO ANTI-FACTOR XIa (FXIa) DE LA COAGULACION |
| CN110732023B (zh) * | 2018-07-18 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种her2抗体药物组合物及其用途 |
| EP3898700A1 (en) * | 2018-12-18 | 2021-10-27 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| KR20210151774A (ko) * | 2019-04-16 | 2021-12-14 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 항-FXI/FXIa 항체 및 그 용도 |
| US20230071973A1 (en) * | 2019-12-20 | 2023-03-09 | Anthos Therapeutics, Inc. | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies |
| EP4177274A4 (en) * | 2020-07-02 | 2024-04-03 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
-
2023
- 2023-01-05 TW TW112100422A patent/TW202333789A/zh unknown
- 2023-01-05 EP EP23737076.2A patent/EP4461749A4/en active Pending
- 2023-01-05 US US18/726,599 patent/US20250179213A1/en active Pending
- 2023-01-05 JP JP2024540670A patent/JP2025502861A/ja active Pending
- 2023-01-05 CN CN202380015149.4A patent/CN118382643A/zh active Pending
- 2023-01-05 WO PCT/CN2023/070573 patent/WO2023131213A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240398914A1 (en) | Combination therapy using a factor xii inhibitor and a c-1 inhibitor | |
| TW201420601A (zh) | 抗ｔｓｌｐ抗體之安定調配物 | |
| JP2024506940A5 (https=) | ||
| JP2024508762A5 (https=) | ||
| US12251474B2 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| JP2017536414A5 (https=) | ||
| JP2022532927A5 (https=) | ||
| CN110234353A (zh) | 用于FXIa抗体的新型稳定制剂 | |
| US20200199209A1 (en) | Sost antibody pharmaceutical composition and uses thereof | |
| WO2018223958A1 (zh) | 一种含c-Met抗体药物偶联物的药物组合物及其用途 | |
| JP2024001135A (ja) | Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法 | |
| EP4076511A1 (en) | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies | |
| JP2025502861A5 (https=) | ||
| US20240277839A1 (en) | High concentration formulation and uses thereof | |
| JP2025506427A (ja) | 生物学的製剤の経口送達のための組成物 | |
| CA3258259A1 (en) | POLYTHERAPIES WITH AN ANTI-FACTOR XI/FACTOR XIA ANTIBODY | |
| WO1994022471A1 (fr) | Preparation liquide d'antithrombine iii et procede pour sa stabilisation | |
| JP2024508746A5 (https=) | ||
| CN106459208B (zh) | Tafi和pai-1的双重靶向 | |
| TW202333789A (zh) | 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途 | |
| JP2024543931A5 (https=) | ||
| RU2775692C2 (ru) | Новые стабильные композиции для fxia антител | |
| CN118078988A (zh) | 包含靶向il-17a的抗体药物组合物 | |
| WO2023098694A1 (zh) | 一种抗sost抗体药物组合物及其用途 | |
| RU2020102952A (ru) | Фармацевтическая композиция, содержащая антитела к pcsk-9, и ее применение |